Insights

Léon Spijkers, Korecyte Bio, on In Vivo CAR-T and Pathological Optimism

November 16, 2026

Léon Spijkers spent nine months calling university tech transfer offices before he found the technology that became Korecyte Bio. The London biotech, built on research from King's College London, is developing in vivo CAR-T therapies for solid tumours.

Léon joined Isabel Kennedy, Vector Talent's Business Development Director, for the first episode of Vector Insights, recorded in the run-up to Jefferies and London Life Science Week. Their conversation moves from the science behind Korecyte to the people who pushed Léon towards each step in his career.

From fixing radios to King's College London

As a child, Léon took apart radios and Walkmans to fix them, and he assumed he'd end up in electronics. Taking medicine when he was ill changed that. He couldn't work out how swallowing a pill could repair something inside the body, and that puzzle led him to molecular biology.

His master's research, 25 to 30 years ago, focused on tumour hypoxia, at a time when small molecules dominated oncology and few people saw the immune system as a route to treating cancer. He went on to a PhD in cardiovascular pharmacology in Amsterdam, run jointly with a pharmaceutical company, expecting a career in pharma R&D. During his PhD, much of the industry's R&D left the Netherlands.

That forced a rethink. Léon worked as a project manager at a CRO, then joined the management team of an open innovation campus on Organon's former site, where he brought companies onto the park and led a drug development consortium. Wanting to understand biotech from every angle, he set up Clouvance Consultancy and spent seven to eight years as a co-founder, chief business officer and adviser to therapeutic developers, while also carrying out due diligence for an investor.

When he felt ready to found a company of his own, he spent around nine months contacting tech transfer offices at universities worldwide. King's College London stood out for its technology and for the scientists behind it. The approach brought him back to the hypoxia work he'd started decades earlier, which he describes as "a final step completing a puzzle".

‍

Using low oxygen as a switch

Earlier work on tumour hypoxia tried to target the complex signalling that low oxygen triggers inside cancer cells. Korecyte takes a simpler route. It uses the pathologically low oxygen levels found in solid tumours as a physical switch to activate CAR-T cells, so the cells can do their job whatever is happening with a given tumour's genetic drivers.

Léon admits he was reluctant at first, but the more diligence he did, the more sense the approach made. Korecyte was incorporated in London from day one and is a fully British company, with Léon, a Dutchman, its only non-British member. He says that decision has paid off through the support and expertise the London ecosystem brings.

‍

Why in vivo CAR-T is drawing attention

Autologous CAR-T has shown clear medical benefit but has struggled to become scalable and commercially rewarding, particularly in solid tumours. In vivo approaches generate CAR-T cells inside the patient. Léon points to lower cost, easier scaling, a better patient journey through an off-the-shelf, single-application therapy, and potentially less T-cell exhaustion, since the cells are freshly generated.

He doesn't see it as a contest between modalities. "There will always be a position for autologous CAR-Ts," he says, and the job is working out where each one works best and can still be commercially viable.

He's glad competitors are drawing investor interest to the field too. Investors looking for a modality that brings something new for patients are increasingly landing on in vivo CAR-T for solid tumours, though Léon is clear that nobody has cracked it yet and the hurdles remain significant.

‍

Leading with pathological optimism

Léon says you need "almost a pathological optimism" to lead a cell and gene therapy company today. Most biotechs fail, and raising enough capital while producing the data to convince investors is daunting. Without strong internal drive, he says, the steady stream of rejections would be hard to get past.

His consultancy years helped prepare him. As a consultant he was his own product, with no room for an unproductive day. He also set aside part of his consulting income for business negotiation courses and modular MBA study, building the commercial knowledge he believes scientists need before they step into a CEO role.

He describes that period as a seven-year bridge, and he doesn't think the learning ever finishes. His advice is to develop a thick skin while still listening, since some criticism carries information worth acting on.

‍

What investors want to see

Having sat on the investor side doing due diligence, Léon knows how many business plans land on their desks. A strong pitch deck leads with a clear proposition: the problem and what you're going to deliver. Getting there means cutting much of the science founders find most convincing.

It also means knowing your competitors. If ten companies are developing the same modality and are further down the line, investors need to see why you're faster, cheaper or better. A good team and good data remain the standard answers, but Léon says the whole package has to resonate, and the likely reasons for a no need addressing in the first few minutes.

Trial location is now part of that scrutiny. Five or ten years ago, few companies had to defend their choice of country, whereas investors now expect a reasoned case for Europe, the US, China or elsewhere. Korecyte has run a risk and benefit analysis to decide where its trials should take place.

‍

The nudge to start

Isabel asked Léon about sponsorship, a theme that runs through our Elevate series. He traced it back to the professor who encouraged him to move from his master's into a PhD. The push to found Korecyte came from a former CFO colleague, who told him to do it now, since there's always a reason to wait.

Those nudges can be hard to spot in the moment, he says, though looking back you can usually pinpoint them. He often hears new CEOs talk about imposter syndrome. His answer is to let the decision rest on what you want to achieve and whether it's work you'd want to wake up to every morning.

For women looking to step into leadership, his advice starts with knowing yourself and whether you'll still want the role in two or five years, since the route is long and has to feel worthwhile. From there, he recommends joining groups that help women step up into leadership roles and reaching out to female founders, many of whom are approachable online. More broadly, he says, talk to people across the whole field, because investors, CROs and everyone else together decide which ideas succeed.

‍

Building the team

Asked what he enjoys most as CEO, Léon points to choosing the people around him, a decision he never had as a consultant. Korecyte's CSO is the inventor of its technology, and Léon credits the CFO, board and investors for the expertise and personality they bring. He calls working with a great team on difficult projects one of the greatest joys the role offers.

Léon is pitching at LSX Investival during London Life Science Week. You can listen to the full conversation on [Spotify link]. Vector Insights sits alongside Elevate, our series with women leading the way in life sciences, and shares the conversations we have across our network and at the industry's biggest events.

If you're building the leadership team behind a growth-stage biotech, speak to our biotech team about the hires that will take you to the next stage.

Speak to our team

Posted by

James Diemar

Industry
You May also like